Tags

Type your tag names separated by a space and hit enter

Severe COVID-19: NLRP3 Inflammasome Dysregulated.
Front Immunol. 2020; 11:1580.FI

Abstract

SARS-CoV-2 might directly activate NLRP3 inflammasome resulting in an endogenous adjuvant activity necessary to mount a proper adaptive immune response against the virus. Heterogeneous response of COVID-19 patients could be attributed to differences in not being able to properly downregulate NLRP3 inflammasome activation. This relates to the fitness of the immune system of the individual challenged by the virus. Patients with a reduced immune fitness can demonstrate a dysregulated NLRP3 inflammasome activity resulting in severe COVID-19 with tissue damage and a cytokine storm. We sketch the outlines of five possible scenarios for COVID-19 in medical practice and provide potential treatment options targeting dysregulated endogenous adjuvant activity in severe COVID-19 patients.

Links

PMC Free PDF

Authors+Show Affiliations

van den Berg DF
Amsterdam UMC, Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, Netherlands.
Te Velde AA
Amsterdam UMC, Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam, Netherlands.

MeSH

BetacoronavirusCOVID-19Coronavirus InfectionsCytokinesHMGB1 ProteinHumansInflammasomesMacrophage ActivationMacrophagesNLR Family, Pyrin Domain-Containing 3 ProteinNeutrophil InfiltrationNeutrophilsPandemicsPneumonia, ViralSARS-CoV-2

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32670297

Citation

van den Berg, Daan F., and Anje A. Te Velde. "Severe COVID-19: NLRP3 Inflammasome Dysregulated." Frontiers in Immunology, vol. 11, 2020, p. 1580.
van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. Front Immunol. 2020;11:1580.
van den Berg, D. F., & Te Velde, A. A. (2020). Severe COVID-19: NLRP3 Inflammasome Dysregulated. Frontiers in Immunology, 11, 1580. https://doi.org/10.3389/fimmu.2020.01580
van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. Front Immunol. 2020;11:1580. PubMed PMID: 32670297.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Severe COVID-19: NLRP3 Inflammasome Dysregulated. AU - van den Berg,Daan F, AU - Te Velde,Anje A, Y1 - 2020/06/26/ PY - 2020/05/13/received PY - 2020/06/15/accepted PY - 2020/7/17/entrez PY - 2020/7/17/pubmed PY - 2020/7/28/medline KW - COVID-19 KW - HMGB1 KW - NLRP3 inflammasome KW - endogenous adjuvant activity KW - therapy SP - 1580 EP - 1580 JF - Frontiers in immunology JO - Front Immunol VL - 11 N2 - SARS-CoV-2 might directly activate NLRP3 inflammasome resulting in an endogenous adjuvant activity necessary to mount a proper adaptive immune response against the virus. Heterogeneous response of COVID-19 patients could be attributed to differences in not being able to properly downregulate NLRP3 inflammasome activation. This relates to the fitness of the immune system of the individual challenged by the virus. Patients with a reduced immune fitness can demonstrate a dysregulated NLRP3 inflammasome activity resulting in severe COVID-19 with tissue damage and a cytokine storm. We sketch the outlines of five possible scenarios for COVID-19 in medical practice and provide potential treatment options targeting dysregulated endogenous adjuvant activity in severe COVID-19 patients. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/32670297/Severe_COVID_19:_NLRP3_Inflammasome_Dysregulated_ DB - PRIME DP - Unbound Medicine ER -